Evicenter
P&T meetings

Juvmo

Parkinson's disease

Also known as tavapadon, CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
217 sources

Section 6 of 6

References

217 sources

  1. Aamodt et al. (2024) (opens in a new tab)
  2. AAN (2021) (opens in a new tab)
  3. Aarsland et al. (2010) (opens in a new tab)
  4. AbbVie Cerevel acquisition completion release (2024) (opens in a new tab)
  5. AbbVie comments to ICER (2026) (opens in a new tab)
  6. AbbVie earnings call transcript (2026) (opens in a new tab)
  7. AbbVie Form 10-K (2026) (opens in a new tab)
  8. AbbVie JUVMO prescriber website (2026) (opens in a new tab)
  9. AbbVie press release (2025) (opens in a new tab)
  10. AbbVie TEMPO-1 topline release (2024) (opens in a new tab)
  11. AbbVie TEMPO-2 topline release (2024) (opens in a new tab)
  12. Ahlskog and Muenter (2001) (opens in a new tab)
  13. Albarmawi et al. (2022) (opens in a new tab)
  14. Allen et al. (2013) (opens in a new tab)
  15. American Academy of Neurology (2020) (opens in a new tab)
  16. Antonini et al. (2008) (opens in a new tab)
  17. Antonini et al. (2018) (opens in a new tab)
  18. Armstrong and Okun (2020) (opens in a new tab)
  19. Arnold et al. (2025) (opens in a new tab)
  20. ARY News (2026) (opens in a new tab)
  21. Azilect prescribing information (2020) (opens in a new tab)
  22. Bain Capital (2018) (opens in a new tab)
  23. Barone et al. (2009) (opens in a new tab)
  24. Benzinga (2026) (opens in a new tab)
  25. Berg et al. (2015) (opens in a new tab)
  26. Bezard et al. (2024) (opens in a new tab)
  27. Bjornestad et al. (2016) (opens in a new tab)
  28. Bjornestad et al. (2017) (opens in a new tab)
  29. Bloem et al. (2021) (opens in a new tab)
  30. Broen et al. (2016) (opens in a new tab)
  31. CADTH (2020) (opens in a new tab)
  32. California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026) (opens in a new tab)
  33. Centers for Medicare and Medicaid Services Part D Spending by Drug (2026) (opens in a new tab)
  34. Centers for Medicare and Medicaid Services Part D Spending by Drug (2026) (opens in a new tab)
  35. Cerevel Therapeutics Form 10-K (2024) (opens in a new tab)
  36. Cerevel Therapeutics press release (2024) (opens in a new tab)
  37. Cerevel Therapeutics statistical analysis plan (2024) (opens in a new tab)
  38. Cerevel Therapeutics TEMPO-1 protocol (2023) (opens in a new tab)
  39. Cerevel Therapeutics TEMPO-1 statistical analysis plan (2024) (opens in a new tab)
  40. Cerevel Therapeutics TEMPO-2 protocol (2023) (opens in a new tab)
  41. Cerevel Therapeutics TEMPO-2 statistical analysis plan (2024) (opens in a new tab)
  42. Cerevel Therapeutics trial protocol (2023) (opens in a new tab)
  43. Chapuis et al. (2005) (opens in a new tab)
  44. Chaudhuri et al. (2015) (opens in a new tab)
  45. ClinicalTrials.gov NCT01981694 (opens in a new tab)
  46. ClinicalTrials.gov NCT02066909 (opens in a new tab)
  47. ClinicalTrials.gov NCT02224664 (opens in a new tab)
  48. ClinicalTrials.gov NCT02224664 (opens in a new tab)
  49. ClinicalTrials.gov NCT02373072 (opens in a new tab)
  50. ClinicalTrials.gov NCT02687542 (opens in a new tab)
  51. ClinicalTrials.gov NCT02687542 (opens in a new tab)
  52. ClinicalTrials.gov NCT02847650 (opens in a new tab)
  53. ClinicalTrials.gov NCT03121664 (opens in a new tab)
  54. ClinicalTrials.gov NCT03185481 (opens in a new tab)
  55. ClinicalTrials.gov NCT04201093 (opens in a new tab)
  56. ClinicalTrials.gov NCT04201093 (opens in a new tab)
  57. ClinicalTrials.gov NCT04223193 (opens in a new tab)
  58. ClinicalTrials.gov NCT04223193 (opens in a new tab)
  59. ClinicalTrials.gov NCT04241393 (opens in a new tab)
  60. ClinicalTrials.gov NCT04295642 (opens in a new tab)
  61. ClinicalTrials.gov NCT04542499 (opens in a new tab)
  62. ClinicalTrials.gov NCT04542499 (opens in a new tab)
  63. ClinicalTrials.gov NCT04760769 (opens in a new tab)
  64. ClinicalTrials.gov NCT05404529 (opens in a new tab)
  65. ClinicalTrials.gov NCT05404542 (opens in a new tab)
  66. ClinicalTrials.gov NCT05581823 (opens in a new tab)
  67. ClinicalTrials.gov NCT05610189 (opens in a new tab)
  68. ClinicalTrials.gov NCT06895356 (opens in a new tab)
  69. ClinicalTrials.gov NCT07158827 (opens in a new tab)
  70. CMS Quality Payment Program measure 291 (2026) (opens in a new tab)
  71. CMS Quality Payment Program measure 293 (2026) (opens in a new tab)
  72. Corvol et al. (2018) (opens in a new tab)
  73. Covington et al. (2016) (opens in a new tab)
  74. Dahodwala et al. (2017) (opens in a new tab)
  75. Dahodwala et al. (2021) (opens in a new tab)
  76. de Bie et al. (2025) (opens in a new tab)
  77. Devraj et al. (2024) (opens in a new tab)
  78. Dickson (2012) (opens in a new tab)
  79. Dodel et al. (2003) (opens in a new tab)
  80. Entacapone tablets prescribing information (2023) (opens in a new tab)
  81. Etminan et al. (2001) (opens in a new tab)
  82. Fahn et al. (2004) (opens in a new tab)
  83. FDA Novel Drug Therapy Approvals (2026) (opens in a new tab)
  84. Fernandez et al. (2023) (opens in a new tab)
  85. Fernandez et al. (2025) (opens in a new tab)
  86. Fernandez et al. (2026a) (opens in a new tab)
  87. Fernandez et al. (2026a) (opens in a new tab)
  88. Fernandez et al. (2026b) (opens in a new tab)
  89. Forsaa et al. (2010) (opens in a new tab)
  90. Forsaa et al. (2015) (opens in a new tab)
  91. Fox et al. (2018) (opens in a new tab)
  92. Fox et al. (2025) (opens in a new tab)
  93. Frazer et al. (2023) (opens in a new tab)
  94. Frequin et al. (2024) (opens in a new tab)
  95. Gage et al. (2003) (opens in a new tab)
  96. GBD 2016 Parkinson's Disease Collaborators (2018) (opens in a new tab)
  97. Gerfen (2022) (opens in a new tab)
  98. Gocovri prescribing information (2026) (opens in a new tab)
  99. Goetz et al. (2008) (opens in a new tab)
  100. Gonzalez et al. (2022) (opens in a new tab)
  101. Gray et al. (2019) (opens in a new tab)
  102. Gros et al. (2025) (opens in a new tab)
  103. Gusovsky et al. (2024) (opens in a new tab)
  104. Hansen et al. (2021) (opens in a new tab)
  105. Harrison-Jones et al. (2025) (opens in a new tab)
  106. Hauser et al. (2000) (opens in a new tab)
  107. Hauser et al. (2004) (opens in a new tab)
  108. Hauser et al. (2011) (opens in a new tab)
  109. Hauser et al. (2014) (opens in a new tab)
  110. Hauser et al. (2025) (opens in a new tab)
  111. Hechtner et al. (2014) (opens in a new tab)
  112. Heinzel et al. (2019) (opens in a new tab)
  113. Hellmers et al. (2025) (opens in a new tab)
  114. Hely et al. (2005) (opens in a new tab)
  115. Hely et al. (2008) (opens in a new tab)
  116. Hickey et al. (2017) (opens in a new tab)
  117. Hjalte et al. (2021) (opens in a new tab)
  118. Hjalte et al. (2025) (opens in a new tab)
  119. Höglinger et al. (2024) (opens in a new tab)
  120. Höglinger et al. (2025) (opens in a new tab)
  121. Horváth et al. (2015) (opens in a new tab)
  122. Horváth et al. (2017) (opens in a new tab)
  123. Houghton et al. (2019) (opens in a new tab)
  124. ICER evidence report (2026) (opens in a new tab)
  125. ICER public meeting slides (2026) (opens in a new tab)
  126. Jimenez-Shahed et al. (2025) (opens in a new tab)
  127. Johnsrud et al. (2021) (opens in a new tab)
  128. Juvmo prescribing information (2026) (opens in a new tab)
  129. Kalf et al. (2012) (opens in a new tab)
  130. Kalilani et al. (2019) (opens in a new tab)
  131. Kaye et al. (2025) (opens in a new tab)
  132. Kim et al. (2020) (opens in a new tab)
  133. Kordower et al. (2013) (opens in a new tab)
  134. Kowal et al. (2013) (opens in a new tab)
  135. Krishna et al. (2023) (opens in a new tab)
  136. Kwak et al. (2024) (opens in a new tab)
  137. Lange et al. (2026) (opens in a new tab)
  138. Leiter et al. (2026) (opens in a new tab)
  139. Lewis et al. (2023) (opens in a new tab)
  140. Łobińska and Sławek (2026) (opens in a new tab)
  141. Macleod et al. (2014) (opens in a new tab)
  142. Macleod et al. (2026) (opens in a new tab)
  143. Makkos et al. (2018) (opens in a new tab)
  144. Marras et al. (2018) (opens in a new tab)
  145. Martínez-Fernández et al. (2020) (opens in a new tab)
  146. Martinez-Martin et al. (2011) (opens in a new tab)
  147. Martinez-Martin et al. (2019) (opens in a new tab)
  148. Medicaid.gov National Average Drug Acquisition Cost (2026) (opens in a new tab)
  149. Medicaid.gov National Average Drug Acquisition Cost (2026) (opens in a new tab)
  150. Mirapex prescribing information (2021) (opens in a new tab)
  151. Neupro prescribing information (2021) (opens in a new tab)
  152. NeurologyLive (2025) (opens in a new tab)
  153. Nguyen et al. (2025) (opens in a new tab)
  154. NICE (2017) (opens in a new tab)
  155. Nourianz prescribing information (2023) (opens in a new tab)
  156. Noyes et al. (2004) (opens in a new tab)
  157. Ondo et al. (2026) (opens in a new tab)
  158. Ongentys prescribing information (2025) (opens in a new tab)
  159. Pahwa and Isaacson (2020) (opens in a new tab)
  160. Pahwa et al. (2023) (opens in a new tab)
  161. Pahwa et al. (2025) (opens in a new tab)
  162. Pahwa et al. (2026) (opens in a new tab)
  163. Palma and Gomez Casanovas (2026) (opens in a new tab)
  164. Pastino et al. (2022) (opens in a new tab)
  165. PD MED Collaborative Group (2014) (opens in a new tab)
  166. Pharmaceutical Technology (2024) (opens in a new tab)
  167. Poewe et al. (2017) (opens in a new tab)
  168. Postuma et al. (2015) (opens in a new tab)
  169. Postuma et al. (2018) (opens in a new tab)
  170. Postuma et al. (2019) (opens in a new tab)
  171. Pringsheim et al. (2021) (opens in a new tab)
  172. Quintas et al. (2024) (opens in a new tab)
  173. Rabinak and Nirenberg (2010) (opens in a new tab)
  174. Rajagopalan et al. (2023) (opens in a new tab)
  175. Ramanzini et al. (2024) (opens in a new tab)
  176. Rascol and Fabbri (2026) (opens in a new tab)
  177. Rashid et al. (2026) (opens in a new tab)
  178. Reijnders et al. (2008) (opens in a new tab)
  179. Requip prescribing information (2021) (opens in a new tab)
  180. Reuters (2026) (opens in a new tab)
  181. Riesenberg et al. (2020) (opens in a new tab)
  182. Rizos et al. (2014) (opens in a new tab)
  183. Rizzo et al. (2016) (opens in a new tab)
  184. Rong et al. (2021) (opens in a new tab)
  185. Rosqvist et al. (2026) (opens in a new tab)
  186. Safarpour et al. (2015) (opens in a new tab)
  187. Sahlholm et al. (2025) (opens in a new tab)
  188. Sako et al. (2023) (opens in a new tab)
  189. Schini et al. (2020) (opens in a new tab)
  190. Schrag et al. (2000) (opens in a new tab)
  191. Schuepbach et al. (2013) (opens in a new tab)
  192. Selegiline hydrochloride capsules prescribing information (2014) (opens in a new tab)
  193. Siderowf et al. (2023) (opens in a new tab)
  194. Simon et al. (2020) (opens in a new tab)
  195. Simuni et al. (2024) (opens in a new tab)
  196. Sisodia et al. (2024) (opens in a new tab)
  197. Sohur et al. (2018) (opens in a new tab)
  198. Stocchi et al. (2010) (opens in a new tab)
  199. Su et al. (2025) (opens in a new tab)
  200. Thach et al. (2021a) (opens in a new tab)
  201. Thach et al. (2021b) (opens in a new tab)
  202. Thach et al. (2021c) (opens in a new tab)
  203. The Lewin Group (2026) (opens in a new tab)
  204. Torres-Russotto et al. (2026) (opens in a new tab)
  205. Verschuur et al. (2019) (opens in a new tab)
  206. Wang et al. (2026) (opens in a new tab)
  207. Weaver et al. (2009) (opens in a new tab)
  208. Weintraub et al. (2010) (opens in a new tab)
  209. Willis et al. (2012) (opens in a new tab)
  210. Willis et al. (2022) (opens in a new tab)
  211. World Parkinson Congress (2026) (opens in a new tab)
  212. Xadago prescribing information (2021) (opens in a new tab)
  213. Yang et al. (2020) (opens in a new tab)
  214. Yao et al. (2023) (opens in a new tab)
  215. Young et al. (2020) (opens in a new tab)
  216. Zhang et al. (2017) (opens in a new tab)
  217. Zhao et al. (2024) (opens in a new tab)